Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma

Endocrinology

Volumn 149, Issue 11, 2008, Pages 5627-5634

  Wuttke, Margret ^a   Papewalis, Claudia ^a   Meyer, Yvonne ^a   Kessler, Caroline ^a   Jacobs, Benedikt ^a   Willenberg, Holger S ^a   Schinner, Sven ^a   Kouatchoua, Christine ^a   Baehring, Thomas ^a   Scherbaum, Werner A ^a   Schott, Matthias ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CALCITONIN; DENDRITIC CELL VACCINE; EPITOPE; GAMMA INTERFERON; TETRAMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNE RESPONSE; INTERFERON PRODUCTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR IMMUNITY;

AMINO ACIDS; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CALCITONIN; CARCINOMA, MEDULLARY; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHIL INFILTRATION; THYROID NEOPLASMS; TUMOR BURDEN;

EID: 54349094277     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0631     Document Type: Article

References (41)

1. Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G 2001 Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1797-1808
2. Samaan NA, Schultz PN, Hickey RC 1989 Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res Suppl 21:21-25
3. Raue F, Kotzerke J, Reinwein D, Schroder S, Roher HD, Deckart H, Hofer R, Ritter M, Seif F, Buhr H 1993 Prognostic factors in medullary thyroid carcinoma: evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7-12
4. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084
5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Corcuff B, Guilhem I 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265-273
6. Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H 2003 Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525
7. Body JJ, Glibert F, Nejai S, Fernandez G, Van LA, Borkowski A 1990 Calcitonin receptors on circulating normal human lymphocytes. J Clin Endocrinol Metab 71:675-681
8. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner, M., Krebs A, Hou J, Schlumberger M 2007 Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. J Clin Oncol 25:2018
9. Schuler G, Schuler-Thurner B, Steinman RM 2003 The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147
10. Schott M, Seissler J 2003 Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies. Trends Endocrinol Metab 14:156-162
11. Schott M 2006 Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer 13:779-795
12. Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J 2001 Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. J Clin Endocrinol Metab 86:4965-4969
13. Schott M, Feldkamp J, Klucken M, Kobbe G, Scherbaum WA, Seissler J 2002 Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 51:663-668
14. Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schuller G, Benko T, Niederle B, Brostjan C, Jakesz R, Gnant M 2002 Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 87:1098-1104
15. Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J 2004 Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 10:2944-2953
16. Mbalaviele G, Jullienne A, De Vernejoul MC 1991 Human umbilical cord blood monocytes express calcitonin receptors in culture in the presence of 1,25 dihydroxyvitamin D. J Clin Endocrinol Metab 72:356-361
17. Bradwell AR, Harvey TC 1999 Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353:370-373
18. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye B, Daly AF, Beckers A 2004 Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 89:3413-3420
19. Ercolini AM, Machiels JP, Chen YC, Slansky JE, Giedlen M, Reilly RT, Jaffee EM 2003 Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol 170:4273-4280
20. Rubio V, Stuge TB, Singh N, Betts MR, Weber JS, Roederer M, Lee PP 2003 Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 9:1377-1382
21. Gold JS, Ferrone CR, Guevara-Patino JA, Hawkins WG, Dyall R, Engelhorn ME, Wolchok JD, Lewis JJ, Houghton AN 2003 A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 170:5188-5194
22. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K 2002 Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169:575-580
23. + T-cell helper epitope 1. Cancer Res 67: 6459-6467
24. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG 2006 Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood 108:3865-3870
25. + T cell repertoires primed with agonist and native peptides derived from a tumor-associated antigen. J Immunol 180:1526-1534
26. Na DH, Youn YS, Park EJ, Lee JM, Cho OR, Lee KR, Lee SD, Yoo SD, DeLuca PP, Lee KC 2004 Stability of PEGylated salmon calcitonin in nasal mucosa. J Pharm Sci 93:256-261
27. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94:3330-3335
28. Sallusto F, Lanzavecchia A 1994 Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 179:1109-1118
29. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway Jr CA 1999 Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 5:1026-1031
30. + T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol 173:6727-6734
31. Wegmann DR, Norbury-Glaser M, Daniel D 1994 Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 24:1853-1857
32. + clones associated with IFN-γ-inducible protein 10 (CXC chemokine ligand 10) production but not cytokine expression, cytolytic activity, or homing characteristics. J Immunol 174:2746-2755
33. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, Eisenbarth GS 2005 Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 435:220-223
34. Moriyama H, Abiru N, Paronen J, Sikora K, Liu E, Miao D, Devendra D, Beilke J, Gianani R, Gill RG, Eisenbarth GS 2003 Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci USA 100:10376-10381
35. Nakayama M, Beilke JN, Jasinski JM, Kobayashi M, Miao D, Li M, Coulombe MG, Liu E, Elliott JF, Gill RG, Eisenbarth GS 2007 Priming and effector dependence on insulin B:9-23 peptide in NOD islet autoimmunity. J Clin Invest 117:1835-1843
36. Jasinski JM, Yu L, Nakayama M, Li MM, Lipes MA, Eisenbarth GS, Liu E 2006 Transgenic insulin (B:9-23) T-cell receptor mice develop autoimmune diabetes dependent upon RAG genotype, H-2g7 homozygosity, and insulin 2 gene knockout. Diabetes 55:1978-1984
37. Cupisti K, Wolf A, Raffel A, Schott M, Miersch D, Yang Q, Eisenberger CF, Roher HD, Knoefel WT 2007 Long-term clinical and biochemical follow-up in medullary thyroid carcinoma: a single institution's experience over 20 years. Ann Surg 246:815-821
38. Zhang R, Scherberg N, DeGroot LJ 1997 Monoclonal antibodies to rat calcitonin: their use in antigenic mapping and immunohistochemistry. Endocrinology 138:1691-1696
39. Zhang R, DeGroot LJ 1997 A monoclonal antibody against rat calcitonin inhibits the growth of a rat medullary thyroid carcinoma cell line in vitro. Endocrinology 138:1697-1703
40. Haupt K, Siegel F, Lu M, Yang D, Hilken G, Mann K, Roggendorf M, Saller B 2001 Induction of a cellular and humoral immune response against preprocalcitonin by genetic immunization: a potential new treatment for medullary thyroid carcinoma. Endocrinology 142:1017-1023
41. Alarcon B, Swamy M, van Santen HM, Schamel WW 2006 T-cell antigen-receptor stoichiometry: pre-clustering for sensitivity. EMBO Rep 7:490-495